<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002715</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-13467</org_study_id>
    <secondary_id>SUMC-G2/G3</secondary_id>
    <secondary_id>CDR0000064551</secondary_id>
    <secondary_id>SQL 76234</secondary_id>
    <secondary_id>NCI-H96-0806</secondary_id>
    <nct_id>NCT00002715</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Pilot Study of Short Term (12 Week) Combination Chemotherapy (Stanford V) in Unfavorable Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have advanced Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of short term chemotherapy with the Stanford V regimen&#xD;
           (mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, bleomycin, and&#xD;
           etoposide) followed by, as indicated, consolidative radiotherapy in patients with stage&#xD;
           IIB, IIIA, IIIB, or IV Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the initial response to 8 weeks of Stanford V chemotherapy in these patients.&#xD;
&#xD;
        -  Assess the complete and partial response rate to 12 weeks of Stanford V chemotherapy in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the acute toxicity associated with this treatment.&#xD;
&#xD;
        -  Determine the disease free interval and survival following Stanford V chemotherapy with&#xD;
           or without consolidative radiotherapy in these patients.&#xD;
&#xD;
      OUTLINE: All patients are treated on Regimen A with the Stanford V Regimen; those with&#xD;
      initial bulky, residual, or splenic disease who achieve a CR/PR proceed to Regimen B.&#xD;
&#xD;
        -  Regimen A: Patients receive mechlorethamine IV on weeks 1, 5, and 9; doxorubicin and&#xD;
           vinblastine IV on weeks 1, 3, 5, 7, 9, and 11; vincristine and bleomycin IV on weeks 2,&#xD;
           4, 6, 8, 10, and 12; etoposide IV over 30-45 minutes for 2 consecutive days on weeks 3,&#xD;
           7, and 11; and prednisone orally every other day on days 1-84. Treatment continues for&#xD;
           8-12 weeks, depending on response, in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Regimen B: Patients begin radiotherapy 2-4 weeks after completion of Regimen A. Patients&#xD;
           receive radiotherapy to lungs, pleura, and other extralymphatic sites for approximately&#xD;
           5 weeks.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be entered if at least 16 of the first 22&#xD;
      patients respond. As of 03/96, it is expected that a total of 45 patients each with stage&#xD;
      III/IV disease and 40 with unfavorable stage II disease will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1989</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bleomycin sulfate</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stanford V regimen</intervention_name>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mechlorethamine hydrochloride</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
    <description>A component of the Stanford V regimen.</description>
    <arm_group_label>Combination Chemotherapy (Stanford V)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Hodgkin's lymphoma of any histology&#xD;
&#xD;
          -  Unfavorable disease required&#xD;
&#xD;
               -  Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)&#xD;
&#xD;
               -  Locally extensive stage I or II with either of the following:&#xD;
&#xD;
                    -  Mediastinal mass greater than 1/3 the maximum intrathoracic diameter&#xD;
&#xD;
                    -  Two or more extranodal sites&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 60&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior malignancy except nonmelanomatous skin cancer&#xD;
&#xD;
          -  No significant concurrent illness that precludes protocol participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment for Hodgkin's lymphoma&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra J. Horning, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol. 1996;7 Suppl 4:105-8. doi: 10.1093/annonc/7.suppl_4.s105.</citation>
    <PMID>8836420</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. doi: 10.1200/JCO.1995.13.5.1080.</citation>
    <PMID>7537796</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage I adult Hodgkin lymphoma</keyword>
  <keyword>Stage II adult Hodgkin lymphoma</keyword>
  <keyword>Stage III adult Hodgkin lymphoma</keyword>
  <keyword>Stage IV adult Hodgkin lymphoma</keyword>
  <keyword>Adult lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>Adult lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>Adult nodular sclerosis Hodgkin lymphoma</keyword>
  <keyword>Adult mixed cellularity Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

